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ABSTRACT

The pencil beam scanning (PBS) modality for delivering intensity modulated
proton radiation therapy is being adopted quickly. Drawing from the dosimetric
advantages provided by the Bragg Peak, PBS proton therapy has been shown to
produce dose distributions with improved healthy tissue sparing.
Although PBS proton therapy is very promising, lung cancer treatment is
not without its challenges. Rapid tissue density changes and respiratory tumor
motion present a particularly difficult treatment geometry. The tumor moves
continuously within the lung as the patient breathes.
In this project, the dose perturbation of a PBS proton therapy lung plan is
evaluated and time based models of respiratory cycle and radiation delivery of a
pencil beam scanning treatment are created. The combined model of the patient
and machine is referred to as the patient machine time model (PMTM). The PMTM
is used to calculate the respiration rate at which the treatment machine dose
delivery and patient respiration rate produce frequency matching (FM).
Frequency matching between the respiratory cycle and radiation delivery is
demonstrated to reduce intra-fraction dose perturbation. The use of the PMTM to
produce FM provides an advanced tool to mitigate respiratory dose perturbation
with minimal impact on the patient or the treatment delivery time.

iv

TABLE OF CONTENTS

Chapter One Contributions and Background Information ..................................... 1
Problem Statement ............................................................................................ 1
Contributions of this Dissertation ....................................................................... 2
Organization of the Dissertation ........................................................................ 3
Project Description ............................................................................................. 3
Lung Cancer Treatment with Proton Therapy .................................................... 5
Proton Therapy Delivery .................................................................................... 8
Uniform Scanning and Double Scattering ...................................................... 8
Pencil Beam Scanning ................................................................................... 9
Treatment Plan Optimization ........................................................................... 10
Clinical Proton Therapy Cyclotrons ................................................................. 12
Isochronous Cyclotron ................................................................................. 13
Synchrocyclotron .......................................................................................... 15
Chapter Two Literture Review ............................................................................. 19
Respiration Frequency and Amplitude ............................................................. 19
Respiration Frequency ................................................................................. 19
Amplitude ..................................................................................................... 20
4D Diagnostic CT Phase Binning .................................................................... 22
Respiratory Motion in Radiation Therapy ........................................................ 23
Breath-Hold .................................................................................................. 24
Gating ........................................................................................................... 25
v

Scanning Modification .................................................................................. 27
Chapter Three Development of the Patient Machine Time Model ...................... 28
Proton PBS Treatment Field Specification ...................................................... 30
Pencil Beam Scanning Treatment Fields ..................................................... 33
Measurement of Proton PBS Treatment Field Delivery Time .......................... 37
Dose Rate Audio Analysis ............................................................................ 39
Modeling of Proton PBS Treatment Field Delivery Time ................................. 42
Energy Selection System Efficiency ............................................................. 42
Beam Current Request ................................................................................ 44
Proton Fluence Rate .................................................................................... 46
Conversion Between MeV and Range ......................................................... 47
Dose Rate .................................................................................................... 49
Monitor Unit Rate ......................................................................................... 51
Model of Respiratory Cycle .............................................................................. 53
Respiratory Cycle Binning During 4D CT ..................................................... 53
Respiratory Cycle Approximation ................................................................. 54
Frequency Matching ........................................................................................ 59
Chapter Four Application of the Patient Machine Time Model ............................ 66
Multi Field Optimization Dose Reconstruction ................................................. 67
Multi Field Optimization Dose Perturbation Examination ................................. 74
Multi Field Optimization Frequency Matching .................................................. 80
Chapter Five Conclusions and Future Work ....................................................... 84
Conclusions ..................................................................................................... 84
vi

Future Work ..................................................................................................... 84
List of References ............................................................................................... 88
Appendix ............................................................................................................. 95
Vita .................................................................................................................... 106

vii

LIST OF TABLES

Table 3.1. Pencil beam scanning layer definition file parameters ....................... 36
Table 3.2. Pencil beam scanning layer definition spot, interspot, and layer
switching time ............................................................................................... 53
Table 3.3. Field 1 - Layer and respirtation intersection ....................................... 57
Table 3.4. Field 2 - Layer and respiration intersection ........................................ 59
Table 3.5. Field 1 - Layer and respiration intersection ........................................ 62
Table 3.6. Field 2 - Layer and respiration intersection ........................................ 65
Table 4.1. Field 1 - Layer and respiration intersection ........................................ 72
Table 4.2. Field 2 - Layer and respiration intersection ........................................ 73
Table 4.3. Field 1 - Layer and respiration intersection ........................................ 82
Table 4.4. Field 2 - Layer and respiration intersection ........................................ 83

viii

LIST OF FIGURES

Figure 1.1. Depth dose of proton and photon beams [1] ....................................... 5
Figure 1.2. Dose distribution of three field pencil beam scanning proton and
volumetric arc therapy photon lung treatments [3] ......................................... 6
Figure 1.3. Dose volume histogram (DVH) of proton and photon treatments [3] .. 7
Figure 1.4. Double scattering & uniform scanning proton field dose distribution [1]
....................................................................................................................... 9
Figure 1.5. Pencil beam scanning proton field dose distribution [1] .................... 10
Figure 1.6. Simplified Pareto surface from treatment plan optimization [4] ......... 12
Figure 1.7. Magnetic field distribution of an isochronous cyclotron [5] ................ 14
Figure 1.8. Radially increasing magnetic field isochronous cyclotron [5] ............ 15
Figure 1.9. Synchrocyclotron cross section with radially decreasing iron [6] ...... 17
Figure 1.10. Radially decreasing synchrocyclotron magnetic field [6] ................. 17
Figure 1.11. Synchrocyclotron radio frequency and beam cycling [6] ................. 18
Figure 2.1. Respiration rate during various activities [8] ..................................... 20
Figure 2.2. Respiratory amplitude at various locations on the body [9] ............... 21
Figure 2.3. Single respiratory cycle [9] ................................................................ 21
Figure 2.4. 4D CT phase binning [10] ................................................................. 23
Figure 2.5. Cyclic motion of clinical tumor volume (CTV) [11] ............................. 24
Figure 2.6. Breath-hold proton therapy delivery [12] ........................................... 25
Figure 2.7. Respiratory gating signal with low amplitude gate window [13] ........ 26
ix

Figure 2.8. Modified pencil beam scanning pattern [14] ...................................... 27
Figure 3.1. Provision Center for Proton Therapy layout with IBA Proteus Plus
isochronous cyclotron [1] ............................................................................ 29
Figure 3.2. Structures representing organs at risk (OARs) ................................. 31
Figure 3.3. Beam’s eye view of spots intensity and structures outlines .............. 32
Figure 3.4. Two field pencil beam scanning proton therapy lung plan ................ 34
Figure 3.5. Field energy layers and spot parameters .......................................... 34
Figure 3.6. Dose rate monitor .............................................................................. 37
Figure 3.7. Field 1 - Measured dose delivery ...................................................... 38
Figure 3.8. Field 2 - Measured dose delivery ...................................................... 38
Figure 3.9. Pencil beam scanning energy layer Bragg peaks ............................. 40
Figure 3.10. Energy selection system efficiency ................................................. 43
Figure 3.11. Beam current request [nA] .............................................................. 45
Figure 3.12. ESS Efficiency [%] vs Beam current request [nA] ........................... 46
Figure 3.13. Full width half max (FWHM) of the proton beam spot vs. energy ... 48
Figure 3.14. Proton range [cm] to energy [MeV] conversion ............................... 48
Figure 3.15. Dose rate [cGy/s] vs. energy [MeV] ................................................ 50
Figure 3.16. Dose [cGy/10MU] vs. range [cm] .................................................... 51
Figure 3.17. Monitor unit rate [MU/sec] ............................................................... 52
Figure 3.18. Respiration inhale and exhale ......................................................... 55
Figure 3.19. Field 1 – Modeled respiration and dose delivery ............................. 55
Figure 3.20. Field 1 - Layer and respiration intersection ..................................... 56
Figure 3.21. Field 2 – Modeled respiration and dose delivery overlay ................ 58
x

Figure 3.22. Field 2 - Layer and respiration intersection ..................................... 58
Figure 3.23. Field 1 – Respiration and dose delivery .......................................... 61
Figure 3.24. Field 1 - Layer and respiration intersection ..................................... 61
Figure 3.25. Field 2 - Respiration and dose delivery ........................................... 64
Figure 3.26. Field 2 - Layer and respiration intersection ..................................... 64
Figure 4.1. Two field lung proton plan used for model testing ............................. 68
Figure 4.2. Field 1 - Contribution to target coverage using multi field optimization
..................................................................................................................... 68
Figure 4.3. Field 2 - Contribution to target coverage using multi field optimization
..................................................................................................................... 69
Figure 4.4. Field 1 – Modeled respiration and dose delivery overlay .................. 71
Figure 4.5. Field 1 – Modeled respiration and dose delivery intersection ........... 71
Figure 4.6. Field 2 – Modeled respiration and dose delivery overlay .................. 72
Figure 4.7. Field 2 – Modeled respiration and dose delivery intersection ........... 73
Figure 4.8. Field 1&2 – Dose delivered to Full Inhale CT phase ......................... 75
Figure 4.9. Composite treatment plan dose on Single Phase of 4D CT .............. 77
Figure 4.10. Reconstructed composite treatment plan dose using each energy
layer’s corresponding 4D CT phase as predicted by the PMTM .................. 77
Figure 4.11. Dose line for comparison of unperturbed dose and patient machine
time model delivery ...................................................................................... 78
Figure 4.12. Difference between unperturbed dose and patient machine time
model delivery .............................................................................................. 79
Figure 4.13. Difference between nominal dose and modeled perturbed delivery 79
xi

Figure 4.14. Field 1 – Predicted frequency matching using the patient machine
time model .................................................................................................... 81
Figure 4.15. Field 1 – Respiratory amplitude at each energy layer ..................... 81
Figure 4.16. Field 2 – Predicted frequency matching using the patient machine
time model .................................................................................................... 82
Figure 4.17. Field 2 – Respiratory amplitude at each energy layer ..................... 83
Figure 5.1. Respiration rate measurement at CT treatment simulation ............... 87
Figure A.1. Field 1&2 – Dose delivered to 80% inhale CT phase ....................... 97
Figure A.2. Field 1&2 – Dose delivered to 60% inhale CT phase ....................... 98
Figure A.3. Field 1&2 – Dose delivered to 40% inhale CT phase ....................... 99
Figure A.4. Field 1&2 – Dose delivered to 20% inhale CT phase ..................... 100
Figure A.5. Field 1&2 – Dose delivered to full exhale CT phase ....................... 101
Figure A.6. Field 1&2 – Dose delivered to 20% exhale CT phase .................... 102
Figure A.7. Field 1&2 – Dose delivered to 40% exhale CT phase .................... 103
Figure A.8. Field 1&2 – Dose delivered to 60% exhale CT phase .................... 104
Figure A.9. Field 1&2 – Dose delivered to 80% exhale CT phase .................... 105

xii

ABBREVIATIONS

PMTM

Patient Machine Time Model

FM

Frequency Matching

CT

Computed Tomography

4D CT

Four Dimensional Computed Tomography

IMPT

Intensity Modulated Proton Therapy

PLD

Pencil beam scanning Layer Definition

FWHM

Full Width Half Max

ESS

Energy Selection System

US

Uniform Scanning

DS

Double Scattering

SOBP

Spread Out Bragg Peak

VMAT

Volumetric Arc Therapy

RF

Radio Frequency

ITV

Internal Target Volume

PTV

Planning Target Volume

GTV

Gross Tumor Volume

ICTV

Internal Clinical Target Volume

IGTV

Internal Gross Tumor Volume

PCPT

Provision Center for Proton Therapy

IBA

Ion Beam Applications

xiii

CHAPTER ONE
CONTRIBUTIONS AND BACKGROUND INFORMATION

Problem Statement

During the past two years, the treatment of thoracic tumors with proton therapy
has shown promise due to increased availability of pencil beam scanning proton
therapy treatment machines. Pencil beam scanning (PBS) proton therapy
treatment plans have demonstrated reduced dose to healthy tissue in treatment of
lung cancer with radiation therapy. Although the dose distribution of proton therapy
treatment plans is promising, the radiation dose is susceptible to perturbation from
respiratory motion.
This dissertation attempts to develop a model of the dose perturbation resulting
from respiratory motion based on the dose delivery of the treatment machine and
the respiration cycle of the patient. The model is termed the patient machine time
model (PMTM). Once the dose perturbation has been evaluated, a dose
perturbation mitigation method is developed to provide minimal impact to the
patient. The developed dose perturbation mitigation method is termed frequency
matching (FM).
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Contributions of this Dissertation
This dissertation makes contributions in the field of radiation therapy specific to
respiratory motion and pencil beam scanning proton therapy. A patient machine
time model (PMTM) has never been applied to the treatment planning process in
proton radiation therapy. A new method to mitigate radiation dose perturbation
from respiratory motion, frequency matching (FM), is also presented. These
contributions, and others, are listed below with a detailed explanation located in
Chapter 3.

1) Development of a model using machine specific parameters to establish
the dose delivery time for pencil beam scanning proton treatment fields
delivered by an isochronous cyclotron based radiation therapy machine.
2) Development of methods to calculate the delivery time of a pencil beam
scanning layer definition (PLD) file included in the treatment plan of a
proton therapy treatment.
3) Development of methods to establish the corresponding respiratory
amplitude during the delivery of each energy layer of a proton treatment
field.
4) Application of the PMTM to reduce dose perturbation by establishing FM
between the dose delivery and respiration cycle.
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Organization of the Dissertation

This dissertation is organized into five chapters. Chapter 1 outlines the
contributions to the field of study as well background information relevant to the
topic of proton therapy and respiratory motion. Chapter 2 provides a literature
review of the investigation of respiratory motion and proton therapy dose delivery.
Chapter 3 includes the description of the data used to build the patient machine
time model. Chapter 4 provides the results and discussion of the application of the
patient machine time model (PMTM). Chapter 5 concludes the dissertation and
discusses the future work related to this research.

Project Description

This project was undertaken to produce a patient machine time model in order to
evaluate dose perturbation from respiratory target motion in radiation therapy. The
possibility of frequency matching (FM) between the patient’s respiratory motion
and the dose delivery of pencil beam scanning proton therapy is also discussed.
This work is significant because it demonstrates the impact of the time scale of the
dose delivery of the treatment machine on the dose distribution of the delivered
radiation therapy treatment. The coupling of the machine delivery and patient
respiratory motion has the potential to reduce uncertainty in radiation therapy. With
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adequate machine characterization, these concepts could be applied to numerous
radiation therapy machines.
In radiation therapy, the unit most commonly used to describe the prescribed
amount of treatment to a target volume is the Gray. Gray is a measure of absorbed
energy per unit mass or Joules per Kilogram. This unit is convenient for much of
radiation therapy because a significant fraction of the human body is of very similar
density to water, allowing easy scaling and conversion between volume and mass.
Photon based radiation therapy has been established as the most prevalent form
of external beam treatment in cancer therapy. Proton therapy has been expanding
rapidly over the past few years due to the promise provided by the Bragg peak
produced by the depth dose curve of a proton beam. Figure 1.1 displays the depth
dose curves of both an 8 Megavoltage (MV) photon beam and a 200 Megaelectron
Volt (MeV) proton beam [1]. Both the Pristine Bragg peak and Spread Out Bragg
peak (SOBP) formed from the addition of multiple smaller Bragg peaks are shown.
Notice that the photon beam produces significantly more entrance dose along its
path to the tumor depth, while the proton beam produces a peak in the dose at the
tumor depth. Another feature of the proton beam depth dose curve is that there is
no significant dose beyond the distal edge of the Bragg peak. In comparison, even
though the photon beam experiences exponential attenuation, the photon depth
dose curve still demonstrates significant exit dose. An example of photon and
proton based radiation therapy plans with multiple fields is discussed below.
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Figure 1.1. Depth dose of proton and photon beams [1]

Lung Cancer Treatment with Proton Therapy

Lung cancer is one of the most common cancers in both men and women.
According to the American Cancer Society, about 14% of all cancer cases will be
lung cancer cases, resulting in almost 225,000 new lung cancer cases in 2016 [2].
Both photon and proton radiation therapy are often used to treat lung cancer.
There is growing interest in proton therapy use in lung cancer treatments due to
its improved dose distribution. The improved dose distribution treats less healthy
tissue, such and the heart and the opposite lung. Figure 1.2 displays the dose
distributions of a proton therapy lung treatment plan on the left and a photon based
treatment plan on the right [3]. The proton plan utilizes three treatments fields
5

while the photon plan is based on an intensity modulated arc referred to as
volumetric arc therapy (VMAT). The distributions of these two treatment plans
provide an interesting comparison between the modalities because they subtend
a similar fraction of the 360° available treatment arc.
In Figure 1.2, the heart is located in the center of the axial CT slice. The dose
distribution displayed in the figure shows a range of dose from 63 Gray shown in
Red, 30 Gray in green, and everything below 20 Gray displayed in blue. It is
important to take note of the increased dose to the heart and lungs shown by the
photon plan in the right side of the figure.

Figure 1.2. Dose distribution of three field pencil beam scanning proton and
volumetric arc therapy photon lung treatments [3]
Figure 1.3 demonstrates the dose to the internal clinical target volume (ICTV)
along with several other organs at risk (OARs), such as the heart and remainder
of the lung [3]. The internal gross tumor volume (IGTV) designates the location of
6

the tumor expanded to include the entire respiration cycle motion.
Notice the significant reduction in dose to healthy organs shown by the proton
dose. More than 20% of the heart received 20 Gray with the photon plan but the
proton plan spared almost all of the heart from reaching this dose level. The dose
to the heart is shown by the red dotted line and the dose to the lung by the black
dotted line.

Figure 1.3. Dose volume histogram (DVH) of proton and photon treatments [3]
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Proton Therapy Delivery

Uniform Scanning and Double Scattering
There are three types of proton dose deliveries: double scattering (DS), uniform
scanning (US), and pencil beam scanning (PBS). Both DS and US create a uniform
dose cube which is then modified with an aperture and compensator to match the
tumor shape. The dose distribution produced by DS and US delivery techniques is
shown in Figure 1.4 [1]. Notice that the high dose profile maintains the same
square width in depth even though the tumor does not have this full width at the
lateral edges of the field. These dose tails are the remnants of the original
distribution of dose being in the shape of a cube.
In order to conform the dose distribution to the distal edge of the tumor, the cube
of dose is deformed by the aperture and compensator. The aperture cuts the field
down to the cross sectional area of the target and the compensator contours the
dose to the distal edge of the target. The piece labeled 1 in the compensator is the
inverse of the depth of the distal edge of the tumor. The compensator is thinner
where the distal edge of target area is deepest and thinner where the distal edge
is shallower. The second piece of the compensator is used to compensate for the
curvature of the patient, and it is thicker where the target depth is shallower and
thinner where the target depth is deeper. The third piece represents additional
compensator thickness to offset the reduced water equivalent thickness cause by
the air pocket inhomogeneity.
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Figure 1.4. Double scattering & uniform scanning proton field dose distribution [1]

Pencil Beam Scanning
Pencil beam scanning (PBS) proton therapy is a type of treatment delivery that is
comprised of individual beamlets. Each of these beamlets is deflected to
transverse to the primary beams direction by scanning magnets in both the X and
Y directions. In order to match the depth of the distal edge of the target volume the
energy of the proton beam entering the patient is modulated by an energy degrader
upstream of the scanning magnets. As the energy of the proton beam entering the
patient is reduced, its range in the patient is also reduced. Figure 1.5 [1] displays
the deflection of the proton beam by the scanning magnets to deliver dose to each
spot on in the tumor, shown in red.
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Figure 1.5. Pencil beam scanning proton field dose distribution [1]

Treatment Plan Optimization
PBS proton therapy plans are created with a process known as inverse planning.
During inverse planning, the dosimetric goals for target coverage and organ
sparing are given as an optimization problem. The solution to the inverse planning
problem is solved through an iterative process of recalculating the dose of each
beamlet in the treatment field until an optimal solution is found. An optimal solution
occurs at the intersection of the multivariable surface representations of what is
possible and what is preferable. The surface created by perfect substitution of
solutions is called a Pareto surface. A Pareto surface is named after an Italian
engineer and economist, Vilfredo Pareto, who first presented the concept in the
field of economics as a country’s production possibilities frontier.
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Figure 1.6 illustrates a simplified visualization of a multi criteria optimization (MCO)
problem often used to find solutions for PBS proton therapy treatment plans [4].
The optimal solution exists when what is possible intersects the surface of what is
desirable. In this example the marginal rate of substitution (MRS) represents the
surface of the limits of possibility, and the marginal rate of transformation (MRT)
represents the tradeoffs between what is preferable. In this simplified problem, the
MRS represents the Pareto surface on which dose to Organ 1 cannot be reduced
without increasing the dose to Organ 2 and vice versa. The MRT curve represents
the physician’s preference for substitution between dose to Organ 1 and Organ 2.
Curves 1 through 4 represent parallel shifts of the trade-off between dose to each
organ showing increasing utility.
The preferences represented by this curve would be the clinical goals of the
physician, ultimately representing an increasingly positive outcome for the patient.
The intersection of what is possible from a given treatment modality such as PBS
proton therapy would be represented by the MRS curve. The MRT curve
represents what is clinically desirable. The intersection of what is possible and
what is desirable is shown when MRS equals MRT and defines the optimally
deliverable treatment plan for that modality. The same concepts would be applied
in photon treatment planning but with a different shape to the MRS curve.
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Figure 1.6. Simplified Pareto surface from treatment plan optimization [4]

Clinical Proton Therapy Cyclotrons

Many of the proton therapy system in the United States are cyclotron based
systems. In order to reach the deepest treatment fields most clinical proton therapy
cyclotrons produce a beam with a final beam energy of at least 230 MeV. There
are two types of cyclotrons that are used to produce the proton beams in this
energy range: isochronous cyclotrons and synchrocyclotrons. The primary
difference between the two types of cyclotrons is the structure of the magnetic field
they use to confine the proton beam.
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1) Isochronous cyclotrons consist of a radially increasing magnetic
field and a constant radio frequency (RF) accelerating voltage
frequency. This radially increasing magnetic field creates a
defocusing force which must be compensated by passing the proton
beam through magnetic poles of alternating strength, call “hills” and
“valleys”.

2) Synchrocyclotrons use a radially decreasing magnetic field and a
variable RF accelerating voltage frequency. This radially decreasing
magnetic field allows for a phenomena called weak focusing. The
radially decreasing magnetic field reduces the need for the beam to
pass through magnetic poles of alternating strength but creates the
need for a variable frequency accelerating RF.

Isochronous Cyclotron

Figure 1.7 displays the magnetic field distribution of an isochronous cyclotron. The
isochronous cyclotron displayed in Figure 1.7 is a four sector machine, producing
four “hills” of high strength magnetic field and four “valleys” of reduced strength
magnetic field [5]. This alternating magnetic field strength produces a restorative
force, keeping the individual particles within the accelerating plane of the cyclotron.
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Figure 1.7. Magnetic field distribution of an isochronous cyclotron [5]

As a proton is accelerated to its final extraction energy of over 230 MeV, the
particle begins to become relativistic and experiences a relativistic mass gain. This
increase in mass results in a reduced charge-to-mass ratio of the accelerating
proton. The radially increasing magnetic field of the isochronous cyclotron, shown
in Figure 1.8, compensates for the relativistic mass gain and keeps the procession
frequency of the accelerating proton in phase with the RF accelerating voltage from
the inner orbitals of the cyclotron until the final extraction energy [5].
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Figure 1.8. Radially increasing magnetic field isochronous cyclotron [5]

Synchrocyclotron

Synchrocyclotrons use a radially decreasing magnetic field and a variable RF
accelerating voltage frequency. This radially decreasing magnetic field allows for
a phenomena called weak focusing, removing the need for the beam to pass
through magnetic poles of alternating strength. Figure 1.9 [6], displays a vertical
cross-section of a synchrocyclotron along its rotational axis of symmetry taken
from a magnetic field simulation in Opera [7]. Opera is a physics simulation
software that is commonly used to design the magnetic field of particles accelerator
components such as cyclotrons, dipoles and quadrupoles.
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Cyclotrons are symmetric rotationally along the vertical axis as well as along the
mid-plane. This symmetry allows the magnetic field simulation to be simplified to a
single quadrant. The magnetic field components are used to confine and steer
charged particles using the Lorenz force, F = q ( v x B ). Where F is the force, q is
the particle charge, v is the velocity vector, and B is the magnetic field vector.
The blue volume, shown in Figure 1.9, represents the magnetized steel of the
cyclotron and the multicolored component represents a cross-section of the
solenoid coil used to magnetize it [6]. The color gradient in the figure shows the
magnetic field, B [Tesla], ranging in strength from nearly zero, in blue, to up to over
5.7 Tesla, in red. The gradual reduction in the amount of steel during the first
400mm of distance from the center of the cyclotron is most pronounced between
the radii of 300 mm and 400 mm. This reduction in steel produced a reduction in
magnetized material and results in the characteristic radially decreasing magnetic
field shown in Figure 1.10 [6].
Although the magnetic field within a synchrocyclotron is simplified when compared
to an isochronous machine, the accelerating RF voltage frequency must still be
matched to the procession frequency of the accelerating protons orbiting in the
cyclotron. In order to produce an accelerating voltage that is in phase with the
accelerating proton the RF frequency must be ramped down as the proton reaches
higher energies and becomes more relativistic. Figure 1.11 demonstrates the ramp
down of RF accelerating frequency, shown by the blue line between the beam
capture and beam extraction windows shown in green dotted lines [6].
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Figure 1.9. Synchrocyclotron cross section with radially decreasing iron [6]

Figure 1.10. Radially decreasing synchrocyclotron magnetic field [6]
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Figure 1.11. Synchrocyclotron radio frequency and beam cycling [6]

The example synchrocyclotron shown in Figure 1.9 would produce a proton beam
extraction once every millisecond, resulting in a proton pulse frequency of 1 kHz.
The pulse structure of a synchrocyclotron is much different than an isochronous
cyclotron which produces proton beam pulses at the same frequency as the
primary accelerating RF frequency of 50-100 MHz. The isochronous cyclotron
beam can be treated as a continuous beam because the pulse frequency is
extremely high. This may not be the case for synchrocyclotrons.
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CHAPTER TWO
LITERTURE REVIEW

This section will review the previous work pertaining to respiratory tumor target
motion and radiation therapy, particularly in the area of lung cancer treatments
performed with pencil beam scanning (PBS) proton radiation therapy. Several
other techniques for respiratory target motion mitigation are also reviewed. It
should be noted that lung cancer treatment with PBS proton therapy is available
at very few facilities which is why it is of particular interest at this time.

Respiration Frequency and Amplitude
The rate at which the patient is breathing along with the distribution of the patients
inhale and exhale phases are necessary in order to create an accurate model of a
patient’s respiration.

Respiration Frequency
Figure 2.1 displays various respiration rates. The most relevant is that of the lying
respiration rate, “LIE”, at nearly 15 breaths per minute [8]. This respiration rate is
significant because all of the PBS proton radiation therapy treatments at the
Provision Center for Proton Therapy (PCPT) are conducting in the lying position,
with the majority completed with the patient lying on their back. In Figure 2.1, the
solid line represents a respiratory inductive plethysmograph (RIP) in which the
respiration rate is measured with a traditional belt potentiometer around the
19

patient’s

chest.

The

dotted

line

represents

an

ambulatory

inductive

plethysmograph (AIP) which tracts the respiration rate with a set of sensors on the
patient’s chest, allowing the patient to have greater mobility.

Figure 2.1. Respiration rate during various activities [8]

Amplitude
Figure 2.2 shows the relationship between the volumetric flow of air through the
oral cavity and that of the expansion of the chest and movement of the diaphragm
[9]. Figure 2.3 displays a typical time distribution of the inhale and exhale phases
of the respiratory cycle [9]. This distribution was the basis of the distribution used
to build the patient machine time model presented in Chapter 3. It is important to
note that the inhalation of a volume of air precedes the rising of the chest.
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Figure 2.2. Respiratory amplitude at various locations on the body [9]

Figure 2.3. Single respiratory cycle [9]
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PNT refers to pneumotachograph, which directly measures the airflow rate out of
the patient’s oral cavity. Body plethysmography (BP) is a measure of the
respiration volume. Respiratory inductive plethysmography (RIP) is a measure of
the physical displacement of the rib cage (RC) or the abdomen (ABD). Depending
on the sensors used to determine the respiratory amplitude a phase lag may need
to be determined in order to correspond to the respiratory amplitude of the internal
patient anatomy.

4D Diagnostic CT Phase Binning

Four dimension computed tomography (4D CT) refers to a computed tomography
diagnostic scan that is acquired while the respiratory amplitude is recorded. The
4D CT scan is acquired in all three spatial directions as well as over an extended
period of time. The forth component, time, creates the four dimensions of a 4D CT.
During a 4D CT, numerous CT slices of the patient are obtained at multiple
respiratory amplitudes which are then sorted into full diagnostic quality CT scans
at all of the respiratory amplitude phases. Figure 2.4 displays the concepts behind
4D CT binning [10]. The top part of the figure shows the ideal 4D CT acquisition.
The CT scanner table is held is position long enough to acquire a CT slice at each
phase of the reparatory cycle and tagged with its corresponding amplitude. The
bottom of Figure 2.4 shows how the slices at the same respiratory amplitude are
combined from multiple table positions. This process should provide 10 full CT
scans of the patient, with one CT scan at each bin of the respiratory amplitude.
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Respiratory Motion in Radiation Therapy

Many methods have been explored to reduce the respiratory motion-induced
dose uncertainty in spot-scanning proton therapy. Unlike a photon beam, a
proton beam has a specific depth at which the majority of its dose will be
delivered. This feature of the proton depth dose allows the potential for greater
respiratory motion dose perturbation than in a photon field delivery.

Figure 2.4. 4D CT phase binning [10]

Lung cancer tumors are often solid masses with a density much closer to water
than the surrounding lung tissue, which is primarily air. Figure 2.5 displays the path
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of the tumor, delineated as the clinical tumor volume (CTV), during a respiration
cycle [11]. In photons the CTV tumor volume is typically expanded to a target
volume that is large enough to include the full cycle of the tumor motion during
respiration, marked internal target volume (ITV). The planning target volume
(PTV), represents the expansion of the ITV for mechanical accuracy of the
patient’s position in the treatment room coordinate system and any possible
movement of the patient’s external anatomy.

Figure 2.5. Cyclic motion of clinical tumor volume (CTV) [11]

Breath-Hold
A breath-hold technique can be used in an attempt to deliver the entire radiation
field in the same respiratory amplitude that the patient is holding their breath.
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Figure 2.6 shows the promising dosimetric results from a study on voluntary breath
hold approach to lung treatment delivery [12]. Image (a) of Figure 2.6 shows the
tight margin around the treatment volume outlined in red provided by the breath
hold technique. Image (b) displays the larger dose perturbation resulting from a
treatment field delivery with the patient is free-breathing.
The primary limitation of breath-hold approach is the short length a patient can
hold their breath. Patients with lung cancer may already have impaired lung
function that prevents them from holding their breath for an extended period of
time. It would be very difficult to use a breath-hold approach for many pencil beam
scanning lung treatment fields, as many have delivery times that extend well over
one minute.

Figure 2.6. Breath-hold proton therapy delivery [12]

Gating
Gating offers an alternative to the breath-hold approach for motion management
that would allow the patient to continue breathing with their natural respiration rate.
Figure 2.7 displays a respiratory cycle with a gate at the lowest amplitude section
of the respiration cycle [13]. The proton beam delivery to the treatment room is
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controlled by the accelerating voltage within the cyclotron with the IBA
ProteusPlus. Future proton therapy system may make use of high speed switching
magnets that will control the beam’s entry into the treatment room. The transition
from RF manipulation to switching magnets may allow for improvements in beam
delivery reliability.
Gating is the most similar to the patient machine time model (PMTM) model and
frequency matching (FM) described in Chapter 3 and appears very promising.
Gating is still limited by the quality of the respiration amplitude measurement during
the treatment field delivery and often requires devices to be attached to the patient
for each fraction.

Figure 2.7. Respiratory gating signal with low amplitude gate window [13]
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Scanning Modification
Several methods have been proposed to modify the scanning pattern of the proton
pencil beam scanning fields to make them less susceptible to respiratory motion.
Figure 2.8 displays typical dose scanning patterns in frames (a) and (b), moving
from left to right [14]. Frame (c) displays the modified scanning pattern which
delivers all of the proton beamlets in the field in a sparser pattern allowing dose to
be delivered over the entire grid through the respiratory cycle. Another approach
suggested increasing the spot size [15], but this would increase the penumbra of
the field.

Figure 2.8. Modified pencil beam scanning pattern [14]
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CHAPTER THREE
DEVELOPMENT OF THE PATIENT MACHINE TIME MODEL

This section will describe the parameters that were used to model the time scale
of the dose delivery from the IBA Proteus Plus proton therapy system located at
the Provision Center for Proton Therapy (PCPT) in Knoxville Tennessee. The time
scale of the dose delivery is then overlaid with a typical patient’s respiratory
amplitude. The PCPT system described in this section makes use of an
isochronous cyclotron and pencil beam scanning. The PCPT facility floor plan
shown in Figure 3.1, displays the isochronous cyclotron in the right most bunker,
represented by a large circular structure [1]. The primary function of analyzing the
system was to identify the time scale of the dose delivery of proton radiation
therapy treatment fields. The project was undertaken with the following goals.

1) Model the interval and length of time the proton beam dose is
delivered within a pencil beam scanning treatment field.
2) Model the respiratory signal used to create 4D CT scans.
3) Couple the treatment machine dose delivery frequency and the
respiratory cycle frequency to establish the patient machine time
model (PMTM).
4) Provide information that can be used as input for treatment planning
and machine delivery to produce frequency matching (FM) between
the patient’s respiration and treatment machine’s dose delivery.
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Similar concepts of dose delivery pulse structure could be used to describe other
systems such as synchrotrons and synchrocyclotrons. Those systems would have
different mechanisms contributing to the dose delivery time scale. The most
significant difference between the isochronous cyclotrons and synchronous
machines is that the pulse structure of the isochronous machine produces a beam
that at the time scale of the treatment field appears as if it is direct current. For a
proton therapy system based on an isochroous cyclotron, the only changes in the
beam delivery are results of the energy degrader and the beam transport system.

Figure 3.1. Provision Center for Proton Therapy layout with IBA Proteus Plus
isochronous cyclotron [1]
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Synchronous machines differ from isochronous machines in that these
accelerators change the frequency of the accelerating voltage to match the kinetic
energy and relativistic correction of the accelerating protons. After the proton beam
reaches its final energy it is extracted and transported down the beamline. In order
to deliver additional protons another bunch of protons must be injected into the
accelerator and the accelerating voltage frequency reset to match the initial energy
of the beam. The accelerating voltage is then ramped up again to match the beam
energy and relativistic corrections. Creating a model of the time structure of dose
delivery for synchronous accelerators would require additional parameters.

Proton PBS Treatment Field Specification

This section describes the parameters of the radiation fields that are sent to the
IBA proton therapy treatment machine from the treatment planning system. These
files are stored in an Oncology information system (OIS) and later transferred to
the treatment machine for patient alignment and radiation delivery.
In order to deliver a pencil beam scanning proton treatment, several pieces of data
are transferred to the treatment machines. The transferred data is comprised of a
computed tomography x-ray based scan of the patient, computer generated
structures to identify organs and target volumes, and the radiation treatment plan.
The radiation treatment plan for PBS is generated by the treatment planning
system and includes a spot map file with the energy, location, and amount of
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monitor units (MU) to be delivered in each spot. This file is referred to as a pencil
beam scanning layer definition file (PLD). MUs are a unit of measure that are
proportional to the dose in the patient. MUs are measured by ionization chambers
in the beam line upstream of the patient. The dose inside the patient in units of
Gray can be accurately delivered as long as the energy of the proton beam is
known along with the amount of monitor units delivered.
Figure 3.2 displays the treatment planning structures created by contouring the
patient’s autonomy on a diagnostic quality CT scan. The CT scan that is acquired
is diagnostic quality and used to both identify the tumor target and the organs at
risk (OARs). In the figure you can see the right lung represented in dark blue, the
left lung in light blue and the heart in red. The target tumor volume is within the
dark blue right lung structure.

Figure 3.2. Structures representing organs at risk (OARs)
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Figure 3.3 shows a visual representation of the individual proton beamlets within
a layer of one field of the treatment plan. The location of the distal edge of the
beamlets, where most of the dose is delivered, is often referred to as the proton
beamlet’s “spot”. The individual beamlets within a treatment field layer are all
delivered at the same energy, in this case 140.5 MeV, shown in the upper left
corner of Figure 3.3.

Figure 3.3. Beam’s eye view of spots intensity and structures outlines

The dose from the spots within the layers is modulated to provide uniform
composite coverage of the target volume. The dose is modulated by varying the
amount of MUs that are delivered to each spot. The MUs from each spot are also
32

displayed in Figure 3.3, the highest MU beamlets are represented with the largest
orange circles while the lower weighted spots shown by small orange circles. The
lowest MU beamlets are shown by and orange “x”, this is done to indicate their
location when the relative size of the MU would have been too small to visualize.
Pencil Beam Scanning Treatment Fields
Pencil beam scanning (PBS) treatment fields use a pair of electromagnets that
deflect the beam perpendicular to its path. One of the magnets scans in the X
direction and the other in the Y direction. The transverse X and Y location of
each spot is specified in the treatment field calculated by the treatment planning
system. These scanning magnets allow the proton beamlets to reach their
specified location. The treatment planning system also specifies the amount of
MUs and the beam energy to deliver each individual spot in the treatment plan.
Each individual spot’s parameters are specified in the treatment plan within a
PLD file.
Treatment Field – Pencil Beam Scanning Layer Definition
The treatment plan used to determine the IBA proton therapy machine parameters
and create a beam model is shown in Figure 3.3. The treatment plan was created
for a tumor target volume in the right lung. The plan is comprised of two posterior
fields. Figure 3.4 shows the energy layers and spot parameters from one of the
treatment fields in the plan. The first energy layer in each field’s PLD is at the
highest energy and all the subsequent energy layers are at sequentially lower
energies.
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Figure 3.4. Two field pencil beam scanning proton therapy lung plan

Figure 3.5. Field energy layers and spot parameters
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Table 3.1 shows the parameters extracted from a portion of the first two layers in
the PLD file. Each energy layer begins with a line that includes the spot tune ID,
proton beam energy in MeV, total monitor units (MUs), location (X and Y) and the
number of spots. The proton beam energy at the start of each layer in column two
is set by the energy degrader.
The spot tune ID refers to the beam optics being used to transport the beam to the
treatment isocenter. The spot tune ID of “4” listed in this PLD file is currently the
only commissioned beam transport tune. Other tunes could be commissioned for
treatment planning with the IBA system but the current tune of “4” represents the
minimum spot size.
At the beginning of the layer and at each individual spot, the total number of MUs
in each energy layer is listed in the third column of the PLD file. The rows in the
PLD with zero monitor units represent tuning pulses, used to accurately position
the beam before the full MUs of the spot are delivered.
The number of spots in an energy layer is listed at the beginning of each layer. The
PLD file used by the IBA system indicates double the amount of spots as in the
treatment planning system because it includes the tuning pulses. Since the amount
of monitor units delivered in the tuning pulses is negligible they are ignored. For
the purpose of this model only the nonzero spots were used.
As shown in Table 3.1, the X and Y locations of the spots in each energy layer are
listed in the first two columns associated with each individual spot. These locations
are given in mm and used by the scanning magnets to position the beam for each
spot.
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Table 3.1. Pencil beam scanning layer definition file parameters
Spot Tune
ID
4
x [mm]
-2.4011037
-2.4011037
4.0348783
4.0348783
-5.619095
-5.619095
0.8168872
0.8168872
-2.4011037
-2.4011037
4.0348783
4.0348783
4
-15.652689
-15.652689
-12.46921
-12.46921
-6.1022496
-6.1022496
0.26471013
0.26471013

MeV
153.0148692
y [mm]
1.9813852
1.9813852
1.9813852
1.9813852
-3.5923386
-3.5923386
-3.5923386
-3.5923386
-9.166062
-9.166062
-9.166062
-9.166062
149.8405041
13.457595
13.457595
7.943646
7.943646
7.943646
7.943646
7.943646
7.943646
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MU
# of Spots
8.347985446
12
0
2.6692247
0
0.10815182
0
0.107137136
0
1.9492636
0
3.4083252
0
0.10588299
51.50052154
0
5.1544304
0
7.7887125
0
0.10519581
0
0.106116466

0
0
0
0
0
0
0
0
0
0
0
0
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0
0
0
0
0
0
0
0

Measurement of Proton PBS Treatment Field Delivery Time

This section will describe the data used to model the time scale of the dose delivery
from the IBA ProteusPlus machine at the Provision Center for Proton Therapy
(PCPT). Parameters were taken both from the treatment planning system
commissioning data and time measurements from proton therapy field deliveries.
Figure 3.6 shows the dose rate monitoring device (DCEU) used to measure the
delivery time of pencil beam scanning layer definition (PLD) files. The DCEU
generates an audio beep when the dose rate exceeds a preset value. The DCEU
was set to alert the user at dose rates above 0.5 Gray per minute. In the case of
pencil beam scanning proton treatment fields, the dose rate exceeds the threshold
to trigger a beep on the dose rate monitoring unit any time the beam is on.
Figures 3.7 and 3.8 show the audio recording of both fields from a lung treatment
plan. The high audio signal corresponds to each energy layer delivery, including
all of the beamlet spots within the layer.

Figure 3.6. Dose rate monitor
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Figure 3.7. Field 1 - Measured dose delivery

Figure 3.8. Field 2 - Measured dose delivery
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Dose Rate Audio Analysis

The proton pencil beam scanning (PBS) treatment field delivery time scale is
dominated by the amount of time the system requires to change between energy
layers. Energy changes are much longer than changing between individual spots
because the energy degrader must be further inserted into the proton beam, to
reduce the range of the proton beam. After the energy has been reduced for the
next energy layer, the entire beam line and gantry optics have to be returned to
match the energy of the treatment layer. Based on the measured dose rate files,
this process requires about 4.385 seconds.

Energy Switching Time

The most significant factor in modeling the time scale of the proton dose delivery
of the IBA machine at PCPT is from energy switching time. Figure 3.7 and Figure
3.8 display audio recordings of the dose rate monitor signal from the secondary
dose recording device (DCEU) shown in Figure 3.6.
Figure 3.9 displays the series of Bragg peaks that comprise a pencil beam
scanning proton therapy field. Each energy layer shown is normalized to the peak
dose making it easy to discern the range, i.e. water equivalent thickness, of each
energy layer in the field. All of the fields used to model the proton PBS lung
treatment fields are delivered with the same structure of higher energy layers
followed by each subsequent lower energy layer.
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Figure 3.9. Pencil beam scanning energy layer Bragg peaks

The audio recordings from the dose rate monitoring beep were analyzed to
calculate the amount of time for the IBA system to change between energy layers.
The audio files were converted into amplitude vectors and analyzed in the forward
and reverse direction.
When analyzing the audio files in the forward direction the start time was detected
when the amplitude exceeded 45% of the maximum audio level. In order to find
the next energy layer start time, the search was resumed three seconds after the
start of the last detected layer. In order to calculate the energy layer end time, the
audio files were analyzed in the reverse direction. The start and end times were
compared for the field deliveries in the example lung treatment plan. Field 1
required an average of 4.383 seconds to transition between energy layers and field
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2 required 4.384 seconds. A value of 4.385 seconds was used in the model of field
delivery time based on this data.

Interspot Dead Time

Interspot dead time refers to the amount of time it takes for the scanning magnets
to transition from on spot position in the PLD to another. This dead time was
calculated in the model to ensure that the length of time for delivery of each layer
in the measured audio matched the length of time in the audio recording. The
model provided a close match to the measured dose delivery with an interspot
dead time of 10 milliseconds.

Monitor Unit Rate Calculation

In order to calculate the time required for each individual spot, the monitor unit
(MU) rate of the system had to be determined. Once the beam current in amperes
(Coulomb/sec) was established for each energy in the clinical delivery range it
could be converted using the stopping power to a dose rate (Gray/sec). After the
dose rate was established for each energy, the system calibration between MUs
and dose (cGy) for each energy was used to determine the MU rate at each energy
(MU/sec).
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Modeling of Proton PBS Treatment Field Delivery Time

This section describes features of the model used to determine the delivery time
of a proton PBS treatment field. Individual parameters of a PBS treatment machine
and pencil beam are evaluated to determine their contribution to the total delivery
time. These parameters include energy selection system (ESS) efficiency, beam
current requested, beam energy and range conversion, dose rate and monitor unit
rate. All of the data was interpolated with a least-squares exponential fit. Fitting the
data allowed the model to include the full range of values used in PLD field
specification. The structure of the exponential fit function is shown in Equation 3.1.
The coefficients A, B, C and D are used to fit the curve to the data.
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Energy Selection System Efficiency
The energy selection system (ESS) used in IBA proton therapy equipment is
located just beyond the cyclotron shown in Figure 3.1. The energy degrader is
located after the proton beam exits the extraction channel of the cyclotron. The
proton beam is extracted at a specific radius and magnetic field. This final
extraction radius results in a final energy of 230 MeV, two thirds the speed of light.
Figure 3.10 shows the ESS efficiency of the IBA proton system at PCPT.
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Figure 3.10. Energy selection system efficiency

After the proton beam is extracted from the cyclotron, an energy degrader is used
to reduce the energy of the proton beam from the final cyclotron extraction energy
down to the specific energy required for each layer within a treatment field. The
ratio of beam current extracted from the cyclotron to that transmitted down the
beam line after the energy degrader and energy selection system is referred to as
the ESS efficiency.
At high energies, the ESS efficiency of the PCPT proton therapy installation are
more comparable to those of the installation at Massachusetts General Hospital
(MGH), 53% vs 40% at 32cm range, but efficiency differs significantly at lower
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energies [16]. The lower energy ESS efficiency at PCPT is improved from the MGH
data, 2.7% vs 1%. The improved ESS efficiency at PCPT is largely due to an
updated degrader design. The PCPT degrader makes use of beryllium rather than
graphite at lower energies, resulting in less scatter and higher ESS transmission
efficiency.

Beam Current Request

The amount of beam current request from the cyclotron is energy dependent. In
order to deliver lower energy proton beams to the treatment room, the energy
degrader must be placed further into the path of the beam. As the protons pass
through the energy degrader, their energy is reduced and thus their water
equivalent depth in the patient is also reduced. In addition to reducing the energy
of the beam the energy degrader also scatters the beam. Some of these scattered
protons result in too large of an angle to be transported down the beam line.
To compensate for the loss of proton transmission efficiency, the IBA system
increases the beam current requested from the cyclotron. This is accomplished by
increasing the output from the ion source at the center of the ion source. This
process is known at beam current feedback. Figure 3.11 displays the range of
beam current requests for different deliveries.
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Figure 3.11. Beam current request [nA]

Shallow treatment fields, such as treatments close to the skin, may request in
excess of 200 nA. Deeper treatment fields that require less energy degrader
insertion, such as prostate treatments, may produce a beam current request of
less than 50 nA. Figure 3.12 shows the inverse relationship between ESS
efficiency and beam current requested. This relationship exists to keep the
downstream beam current in a narrow range to provide stable dose rate
monitoring. The beam current delivery at each energy in the treatment field is the
product of the ESS efficiency multiplied by the beam current requested from the
cyclotron.
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Figure 3.12. ESS Efficiency [%] vs Beam current request [nA]

Proton Fluence Rate

This section describes the calculation of fluence based on the field delivery
parameters of the IBA system. Fluence is a measure of the number of protons per
unit area. The proton fluence rate is calculated across the range of energies used
in clinical proton radiation therapy. The ESS efficiency, full width half max (FWHM),
and beam current request parameters were acquired during commissioning and
during field delivery.
The beam current requested from the cyclotron is an energy dependent parameter
specific to the IBA system. The requested beam current varies with energy to
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ensure that after losses through the ESS and beam transport there is sufficient
beam current for accurate beam measurement downstream of the energy
degrader.
The FWHM is a statistical parameter with a width of 2.355 standard deviations
taken from a Gaussian distribution of the data. The FWHM used to provide the
surface area over which the calculated beam current was delivered. The FWHM
was measured during the clinical commission of the IBA proton therapy equipment
at the Provision Center for Proton Therapy (PCPT) [17]. Figure 3.13 displays the
FWHM of the proton beam at the entrance as a function of energy. The lower
energies have a larger spot size due to lower energies scattering more in air and
additional scatter from passing through a thicker part of the degrader.

Conversion Between MeV and Range

Figure 3.14 shows the relationship used to convert data from range in centimeters
to proton beam energy in megaelectron volts. The conversion was done using
water equivalent range [18].
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Figure 3.13. Full width half max (FWHM) of the proton beam spot vs. energy

Figure 3.14. Proton range [cm] to energy [MeV] conversion
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Dose Rate

This section describes the conversion from beam current to proton fluence rate.
Proton fluence rate was calculated using the delivery spot size (FWHM), ESS
efficiency and beam current request. Equation 3.2 refers to the dose rate
calculation and Equation 3.3 refers to the proton fluence rate. Figure 3.15 shows
the resulting dose rate in cGy per second resulting from the other parameters such
as FWHM, beam current, and stopping power. Equation 3.4 shows, the beam
current used in the dose rate calculation using the product of the beam current
requested from the cyclotron multiplied by the ESS efficiency. Both ESS efficiency
and the beam current request are energy dependent.
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3.4

Monitor Unit Rate

The Monitor Unit (MU) rate is the final piece to establish the dose delivery time
scale from the pencil beam scanning layer definition (PLD) file associate with each
treatment field. Figure 3.16 displays the relationship between MU and dose used
by the treatment planning system to create clinically deliverable treatment fields.
The relationship between entrance dose and range shown in Figure 3.16 was used
to convert the dose rate for each spot in each energy layer into monitor units per
second (MU/s), shown in Figure 3.17. MU/s was the final parameter used to
calculate the time required for each spot at a given energy.

Figure 3.16. Dose [cGy/10MU] vs. range [cm]
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Table 3.2 lists some of the first spots, interspot dead time, and the first energy
change to deliver the second energy layer. The left column represents the time
in seconds while the right hand column lists the does rate in MU/s. Table 3.2 also
demonstrates the 4.385 seconds that is required for the machine to transition
between energy layers. Notice that each spot’s individual delivery time it is
extremely short, often much shorter than the 10 millisecond interspot dead time.
The significant amount of time dedicated to interspot dead time and energy layer
transitions demonstrates the importance of modeling the machines delivery
timescale in order to properly represent the resulting does perturbation that
occurs as result of tumor target motion.

Figure 3.17. Monitor unit rate [MU/sec]
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Table 3.2. Pencil beam scanning layer definition spot, interspot, and layer
switching time

Time [secs]
0.000945517
0.01
0.000225585
0.01
0.000582868
0.01
4.385
0.006075084
0.01
0.017367621
0.01
0.001507805

Dose Rate
[MU/sec]
480.8606824
0
480.8606824
0
480.8606824
0
0
477.1260972
0
477.1260972
0
477.1260972

Model of Respiratory Cycle

Respiratory Cycle Binning During 4D CT
A 4D CT refers to a computed tomography X-ray based diagnostic scan that is
acquired over multiple breathing cycles. This allows CT slices to be captured at all
of the respiratory amplitudes included in a patient’s inhale and exhale. Ultimately
the respiratory inhale and exhale cycle is broken up into 10 individual computed
tomography CT scans. Each of these scans is comprised of all the CT slices
acquired at a certain amplitude during the patient’s inhale or exhale. This results
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in five inhale CT scans and five exhale CT scans taken in 20% amplitude
increments.

Respiratory Cycle Approximation

In order to calculate to which respiratory amplitudes the energy layer delivery
corresponded, a model of the respiratory signal was created. Figure 3.18 displays
one cycle of the respiratory amplitude produced from a breathing rate of 15 breaths
per minute. The model that was developed allows for modification of this
respiration rate, as it will vary from patient to patient. The shape of the respiratory
cycle model is based on a sine wave shown by the blue part of the curve and an
exponential decay shown in the orange part of the curve. The relative lengths of
the inhale and exhale phase are about one third and two thirds, respectively. This
ratio between the inhale and exhale phases of the respiratory cycle is designed to
approximate thoracic respiratory motion. [9]
Figure 3.19 demonstrates the overlay of a 15 breaths per minute respiratory cycle
with the modeled machine delivery time for treatment field 1 and respiratory
amplitude during dose delivery. Figure 3.20 displays the corresponding respiratory
amplitude associated with each energy layer delivery within the treatment field.
The respiratory amplitude and inhalation or exhalation indication allows the dose
from each energy layer to be computed on its corresponding phase of the 4D CT
scan.
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Figure 3.18. Respiration inhale and exhale

Figure 3.19. Field 1 – Modeled respiration and dose delivery
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Figure 3.20. Field 1 - Layer and respiration intersection

Table 3.3 displays the respiratory amplitude during each energy layer delivery
along with an indication as to the inhale or exhale component of the respiratory
cycle. Once each energy layer of field 1 has been computed on its corresponding
4D CT phase, the dose from each 4D CT phase can be deformed onto a single
phase of the 4D CT for evaluation.
Figure 3.21 demonstrates the overlay of a 15 breaths per minute respiratory cycle
with the modeled machine delivery time for treatment field 2. Figure 3.22 displays
the corresponding respiratory amplitude associated with each energy layer
delivery within the treatment field.
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Table 3.3. Field 1 - Layer and respiration intersection
Layer
1
2
3
4
5
6
7
8
9
10
11
12
13

Amplitude In [1] or Ex [-1]
0.17
1
0.47
1
1.00
1
0.60
-1
0.26
-1
0.50
-1
0.79
1
0.32
-1
0.41
-1
0.80
-1
0.35
1
0.17
1
0.66
-1

Table 3.4 displays the respiratory amplitude during each energy layer delivery
along with an indication as to the inhale or exhale component of the respiratory
cycle for field 2. In the third column of the Table 3.4, a “1” indicates an inhale
component of the respiratory cycle and a “-1” indicates an exhale component of
the respiratory cycle. The respiratory amplitude and inhalation or exhalation
indication allows the dose from each energy layer to be computed on its
corresponding phase of the 4D CT scan. Once each energy layer from field 2 has
been computed on its corresponding CT the composite this delivery can be
deformed onto a single phase of the 4D CT for evaluation. The summation of the
deformed dose from field 1 and field 2 gives the composite perturbed dose as
modeled by the PMTM energy layer and respiratory amplitude intersections.
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Figure 3.21. Field 2 – Modeled respiration and dose delivery overlay

Figure 3.22. Field 2 - Layer and respiration intersection
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Table 3.4. Field 2 - Layer and respiration intersection
Layer
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Amplitude In [1] or Ex [-1]
0.17
1
0.53
1
1.00
1
0.64
-1
0.36
-1
0.20
-1
0.55
1
0.94
-1
0.46
-1
0.24
-1
0.25
1
0.92
1
0.80
-1
0.55
-1

Once the corresponding respiratory amplitude and inhalation or exhalation has
been determined for each energy layer delivery in both treatment fields each
energy layer can be recalculated on its corresponding 4D phase.

Frequency Matching

This section demonstrates the potential for frequency matching (FM), which results
when the respiratory frequency and machine frequency are close enough that all
of the energy layers are delivered in the same phase of the 4D CT.
FM could have a significant impact on proton pencil beam scanning (PBS)
treatment delivery by minimizing the necessity for more cumbersome motion
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mitigation approaches such as breath hold techniques or machine gating. Based
on the information from the 4D CT, the treatment plan could be optimized such
that it is deliverable on any phase of the 4D CT. Once the treatment plan has been
optimized across all CT phases, FM could be sufficient by itself. This would entail
measuring the patient’s respiratory rate in the treatment room and matching it to
the machine delivery rate.
Figure 3.23 shows the results of field 1 delivered at a respiration rate of 11.8
breaths per minute. FM allows for all of the energy layers in field 1 to be delivered
at the same respiratory amplitude.
Figure 3.24 displays the respiration amplitude at which each of the energy layers
would be delivered with FM at 11.8 breaths per minute. The plot displays all of the
energy layer deliveries intersecting the respiratory amplitude on a nearly horizontal
line. Synchronizing the respiratory rate with the rate at which energy layers are
delivered allows for FM and an unperturbed dose delivery.
Table 3.5 displays the respiratory amplitude at each intersection of the energy
layers in field 1. FM allows for the layers to all be delivered on the same phase of
the 4D CT. The intersection amplitude ranges from 0.17 to 0.3, normalized to the
maximum respiratory amplitude.
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Figure 3.23. Field 1 – Respiration and dose delivery

Figure 3.24. Field 1 - Layer and respiration intersection
61

Table 3.5. Field 1 - Layer and respiration intersection
Layer
1
2
3
4
5
6
7
8
9
10
11
12
13

Amplitude In [1] or Ex [-1]
0.17
1
0.22
1
0.27
1
0.30
-1
0.28
-1
0.26
-1
0.24
1
0.21
-1
0.18
-1
0.17
-1
0.19
1
0.17
1
0.18
-1

Figure 3.25 shows field 2 delivered at a respiration frequency of 12.4 breaths per
minute. Frequency matching (FM) allows for all of the energy layers in field 2 to be
delivery at the same respiratory amplitude. Figure 3.26 displays the respiration
amplitude at which each of the energy layers would be delivered with FM of field 2
at 12.4 breaths per minute. The increase in the respiration rate to achieve
frequency matching when comparing field 1 to field 2 is most likely due to field 2
having one fewer energy layer, 13 vs 14 energy layers and the individual energy
layers in field 1 being delivered more quickly. When comparing the individual
energy layers within each treatment field, the longest energy layers in field 1,
Figure 3.21, are delivered more quickly than in Figure 3.25, field 2, as shown by
the narrower width of the field 1 energy layers.
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The plot displays all of the energy layer deliveries intersecting the respiratory
amplitude on a nearly horizontal line. Synchronizing the respiratory frequency with
the energy layer delivery allows for FM and an unperturbed dose delivery. Table
3.6 displays the respiratory amplitude at each intersection of the energy layers in
field 2. FM at 12.4 breaths per minute allows for the layers to all be delivered on
the same phase of the 4D CT. The intersection amplitude ranges from 0.17 to 0.22.

63

Figure 3.25. Field 2 - Respiration and dose delivery

Figure 3.26. Field 2 - Layer and respiration intersection
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Table 3.6. Field 2 - Layer and respiration intersection
Layer
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Amplitude In [1] or Ex [-1]
0.17
1
0.19
1
0.21
1
0.21
-1
0.22
-1
0.22
-1
0.21
1
0.20
-1
0.18
-1
0.17
-1
0.18
1
0.18
1
0.20
-1
0.23
-1
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CHAPTER FOUR
APPLICATION OF THE PATIENT MACHINE TIME MODEL

This section will discuss the results of applying the patient machine time model
(PMTM) to a two field lung treatment plan that was evaluated with a fifteen
breathes per minute respiratory rate. The primary purpose of this section is to
demonstrate the use of the PMTM to evaluate the dose perturbation from
respiratory motion. Frequency matching (FM) is also shown by matching the
radiation therapy dose delivery frequency to that of the respiratory frequency.
In this section the respiratory frequency is modified to synchronize with the
treatment machines does delivery frequency. The treatment delivery frequency is
dominated by energy layer switching time with the inter-spot dead time and monitor
unit (MU) delivery rate serving as secondary effects. The treatment machine used
to produce the PMTM currently has a fixed energy layer switching time that is too
slow to match the respiratory rate of 15 breaths per minute. Another option to
achieve FM would be to deliver the energy layers at half the respiration rate to
avoid hitting the energy layer switching rate limit. This should allow for all of the
energy layers to be delivered on the same phase of the 4D CT but would extend
the treatment field delivery time significantly.
Future improvements in technology should allow the energy layer switching time
to be reduced significantly. If the energy layer switching time were reduced from
the 4.384 seconds available in the current system configuration to below 3
seconds, FM could be achieved at the patient’s natural breathing rate.
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Alternatively, the patient’s respiration frequency could be slowed to match the
treatment machine’s energy layer delivery frequency. The patient could be
coached with audio or visual feedback to slow their respiration rate and achieve
FM.

Multi Field Optimization Dose Reconstruction

The section describes the application of the patient machine time model (PMTM)
described in Chapter 3. The model was applied to the following two field treatment
plan in order to calculate the phases of the 4D CT that each energy layer of dose
would be delivered on. Figure 4.1 displays the proton pencil beam scanning
treatment plan calculation on one of the 10 phases of the 4D CT. This is equivalent
to the dose distribution achieved by frequency matching (FM).
Figures 4.2 and Figure 4.3 display the individual dose contributions from each
treatment field. Each individual beam does not provide uniform tumor cover but
rather delivers dose in the area where the combine contributions from each
treatment field produce an optimal dose distribution. The high dose region of field
1, shown in red, is delivered on the left side of the target volume while the high
does from field 2 is delivered on the right side of the target volume. This division
of target coverage between the two fields can leave the plan more susceptible to
target volume motion form respiration.
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Figure 4.1. Two field lung proton plan used for model testing

Figure 4.2. Field 1 - Contribution to target coverage using multi field optimization
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Figure 4.3. Field 2 - Contribution to target coverage using multi field optimization

The treatment plan shown in Figure 4.1 uses multi field optimization (MFO). MFO
is a technique in which each field does not provide uniform coverage of the target
volume. Alternatively, a field optimization strategy where each individual beam
uniformly covers the target volume is known as single field optimization (SFO). An
MFO approach was selected to evaluate the potential impact of the PMTM in
treatment cases with respiratory motion. The MFO type of optimization used in this
example evaluation is not typically applied to targets with respiratory motion
because it is more susceptible to dose perturbation from respiratory motion.
Although MFO treatment plans can be more susceptible to dose to respiratory
motion they are attractive in scenarios requiring more aggressive tissue sparing.
The PMTM developed in this section may provide additional insight into the
expansion of MFO to cases with respiratory target motion.
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Each energy layer of the treatment plan shown in Figure 4.1 will be calculated on
its corresponding 4D CT phase and deformed back to this phase of the 4D CT.
The combined dose will provide a representation of the dose delivery as if the
patient were to breath at 15 breaths per minute. After the composite dose is
evaluated on a single phase of the 4D CT, the respiratory rate to achieve FM will
be calculated to represent the delivery of each energy layer on the same phase of
the 4D CT.
Figure 4.4 and Figure 4.6 display the respiratory amplitude of each energy layer
delivery calculated by the PMTM for treatment field 1 and field 2. The respiratory
rate used in the model was 15 breaths per minute. Figure 4.5 and Figure 4.7
display the corresponding respiratory amplitude associated with each energy layer
delivery within the treatment field. Table 4.1 and Table 4.2 display the respiratory
amplitude during each energy layer. An indication as to the inhale, 1, or exhale, 1, component of the respiratory cycle is displayed in the third column of the table
corresponding to each treatment field. The results of the PMTM shown in Table
4.1 and Table 4.2 were used to calculate the dose from each energy layer onto the
corresponding phase of the 4D CT.
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Figure 4.4. Field 1 – Modeled respiration and dose delivery overlay

Figure 4.5. Field 1 – Modeled respiration and dose delivery intersection
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Table 4.1. Field 1 - Layer and respiration intersection
Layer
1
2
3
4
5
6
7
8
9
10

Amplitude In [1] or Ex [-1]
0.17
1
0.54
1
0.99
1
0.68
-1
0.34
-1
0.20
1
0.99
1
0.57
-1
0.30
-1
0.18
-1

Figure 4.6. Field 2 – Modeled respiration and dose delivery overlay

72

Figure 4.7. Field 2 – Modeled respiration and dose delivery intersection

Table 4.2. Field 2 - Layer and respiration intersection
Layer
1
2
3
4
5
6
7
8
9
10

Amplitude In [1] or Ex [-1]
0.17
1
0.41
1
0.88
1
0.89
-1
0.44
-1
0.20
-1
0.67
1
0.80
-1
0.39
-1
0.22
-1
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Multi Field Optimization Dose Perturbation Examination

This section will discuss the resulting dose perturbation of the patient machine time
model (PMTM) on this two field multi field optimization (MFO) lung treatment plan.
Using the PMTM and frequency matching (FM) the amount of potential dose
perturbation cause by the energy layers of a radiation therapy treatment field being
delivered on numerous different respiratory amplitude can be significantly reduced.
This section will compare the dose distribution from the composite plan using FM
and without FM.
Figure 4.8 displays the dose, without FM, from field 1 and field 2 that was delivered
onto the full inhale phase of the 4D CT. Figure 4.12 shows the dose from both
treatment fields as it was delivered onto the Full Inhale phase of the 4D CT. This
dose distribution displays the result of the energy layers delivered from the
amplitude and exhale or inhale that corresponds to each 4D CT phase. The dose
from the energy layers delivered to the remaining phases of the 4D CT are shown
in the Appendix. The 4D CT phases include: full inhale, 80% inhale, 60% inhale,
40% inhale, 20% inhale, Full exhale, 20% exhale, 40% exhale, 60% exhale, and
80% exhale.
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Figure 4.8. Field 1&2 – Dose delivered to Full Inhale CT phase
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Figure 4.9 displays the composite dose from the treatment plan when FM is utilized
to deliver all of the energy layers on the same respiratory amplitude phase of the
4D CT. As long as FM is used, is it possible to for all of the energy layers to be
delivered on the same phase of the 4D CT during an individual fraction within a
course of treatment.
Figure 4.10 displays the dose distribution when FM is not used. Notice that the
tumor dose distribution is perturbed and no longer uniformly convers the target
volume. This represents the worst case dose perturbation, when the individual
fields do not full cover the target volume.
Figure 4.11 displays an axial comparison of the of the dose distribution on the
phase matched CT in the top section and the dose from each energy layer
delivered onto the corresponding phase of the 4D CT and then deformed back
onto the 4D CT phase on which the unperturbed treatment plan was computed.
Figure 4.12 displays the dose difference between the nominal dose and the
modeled delivery. The dose distribution shown is the result of the PMTM dose
subtracted from the unperturbed dose to show the dose difference. This difference
can be visualized in the plot in Figure 4.13. The dotted line displays the dose on
the PMTM perturbed delivery and the solid line displays the dose distribution of the
unperturbed single respiration phase delivery.
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Figure 4.9. Composite treatment plan dose on Single Phase of 4D CT

Figure 4.10. Reconstructed composite treatment plan dose using each energy
layer’s corresponding 4D CT phase as predicted by the PMTM
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Figure 4.11. Dose line for comparison of unperturbed dose and patient machine
time model delivery
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Figure 4.12. Difference between unperturbed dose and patient machine time
model delivery

Figure 4.13. Difference between nominal dose and modeled perturbed delivery
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Multi Field Optimization Frequency Matching
This section displays the use of the patient machine time model (PMTM) on the
parameters of the two field lung treatment plan shown in Figure 4.1. Figure 4.14
displays the energy layers and respiratory cycle of field 1 at 12.3 breathes per
minute, producing frequency matching (FM). FM in field 2 is achieved at 12.4
breaths per minute, shown in Figure 4.16. As shown previously in Figure 4.13,
dose perturbation from respiratory motion in multi field optimization (MFO) pencil
beam scanning (PBS) proton therapy can be significant. Figure 4.15 and 4.17
display the amplitude of each energy layers’ delivery achieved by FM. Table 4.3
and 4.4 display the narrow range of respiratory amplitude intersections of each
energy layer.
FM allows the composite dose distribution to remain unperturbed with little
impact on the patient or treatment delivery time. The dose distribution achieved
by frequency matching will match the dose distribution of a full treatment delivery
on a single 4D CT phase. This unperturbed treatment delivery resulting from
frequency matching is shown in Figure 4.9.
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Figure 4.14. Field 1 – Predicted frequency matching using the patient machine
time model

Figure 4.15. Field 1 – Respiratory amplitude at each energy layer
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Table 4.3. Field 1 - Layer and respiration intersection
Layer
1
2
3
4
5
6
7
8
9
10

Amplitude In [1] or Ex [-1]
0.17
1
0.19
-1
0.22
-1
0.24
-1
0.22
-1
0.19
-1
0.17
-1
0.17
1
0.18
1
0.17
1

Figure 4.16. Field 2 – Predicted frequency matching using the patient machine
time model
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Figure 4.17. Field 2 – Respiratory amplitude at each energy layer

Table 4.4. Field 2 - Layer and respiration intersection
Layer
1
2
3
4
5
6
7
8
9
10

Amplitude In [1] or Ex [-1]
0.17
1
0.20
-1
0.25
-1
0.28
-1
0.26
-1
0.22
-1
0.19
-1
0.17
-1
0.17
1
0.17
1
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CHAPTER FIVE
CONCLUSIONS AND FUTURE WORK

Conclusions

The use of the patient machine time model (PMTM) in pencil beam scanning
proton therapy could be useful to produce frequency matching (FM) between the
respiratory frequency of the patient and the dose delivery frequency provided by
the treatment machine. FM of the respiratory frequency and the machine delivery
frequency has the potential to mitigate dose perturbation from respiratory target
motion.
To achieve FM, it will be important to measure the respiratory rate of the patient
and match it to the dose delivery rate of the treatment machine. In a frequency
matched PBS proton therapy delivery, the patient may breathe at 14 breaths per
minute and the machine may deliver the treatment field at a rate of 14 energy
layers per minute.

Future Work

The work in this dissertation has demonstrated the potential for the patient
machine time model in pencil beam scanning proton radiation therapy. There are
three key areas for future work to bring frequency matching into clinical practice.
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1) Measure the patient’s respiration rate at the time of the treatment
planning simulation
2) Frequency match the patient’s respiration to the treatment
machine’s delivery
3) Frequency match the treatment machine’s delivery to the patient’s
respiration

A camera based stereoscopic camera system known as No Dose Setup (NDS)
has also been developed to aid in the reproducibility of patient setup for radiation
therapy both in CT treatment simulation and in the treatment room. The system is
currently being used to assist in patient setup as an additional tool, supplementing
the orthogonal x-rays conventionally used to setup the patient. The system allows
initial positioning of the patient to be conducted without radiation exposure. The
NDS system provides real time image fusion between the patient’s current position
and reference target position.
A 10 patient 10 fraction study was conducted to compare traditional orthogonal Xray patient setup with and without the camera based system. The NDS system
was used to supplement setup prior to X-ray imaging. The use of the system
allowed a 23% reduction in the total time the patient stayed in the treatment room
and eliminated 50% of the X-rays used in the iterative process of setting up the
patient.
The NDS system features will be expanded to include respiration rate monitoring
of the patient from the video stream shown in Figure 5.1. The respiration amplitude
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of the patient plotted over time is shown in the lower right corner of the NDS user
interface in Figure 5.1. Significant improvements in respiration motion
management are expected from the additional surface tracking technology of the
NDS system. Surface tracking for patient setup and respiratory motion motioning
should provide improvements in lung cancer treatments both in reduced X-ray
setup imaging exposure and reduced dose perturbation allowed by frequency
matching (FM). Continuous respiration rate monitoring of the patient combined with
dynamic energy layer switching times between 3 and 5 seconds would enable FM
to become the primary dose perturbation mitigation in pencil beam scanning proton
therapy.
Through a collaboration with Oak Ridge National Laboratory (ORNL), Provision
Center for Proton Therapy (PCPT), and George Washington University (GU), a
seed grant was awarded to make progress towards adapting proton therapy
treatment fields to compensate for respiratory motion.
In order to make strides towards real time motion adaptation one must first acquire
an accurate representation of the patient’s respiration rate. The first phase of the
collaboration between ORNL, PCPT, and GU is to develop respiratory rate
monitoring to supplement the stereoscopic camera based patient setup system.
Figure 5.1 displays the image fusion produced by the stereoscopic camera system,
overlaying the patient’s current position and the patient’s previous position. In the
lower right corner of Figure 5.1 shows the envisioned location of the patient’s
respiration rate.
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Figure 5.1. Respiration rate measurement at CT treatment simulation

Once the patient’s respiration rate has been measured, the patient could be
coached to modify their respiration rate slightly. A slight modification of the
patient’s respiration rate at the time of the CT simulation combined with the PMTM
could result in FM of the respiration cycle and dose delivery.
The final phase would be to utilize modifiable machine delivery parameters to
produce FM. This would allow the incorporation of the PMTM into the treatment
planning optimization. This would also allow optimization of the treatment fields to
be deliverable on any of the respiratory amplitudes represented in the ten 4D CT
phases. Along with this optimization, FM would be sufficient to mitigate dose
perturbation from respiratory motion.
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APPENDIX
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In Chapter 4, the model of the multi field optimization dose perturbation makes
reference to the dose that is predicted to be delivered from the treatment plan on
each phase of the 4D CT. This Appendix supplements the Figure 4.8 to provide
the complete set of dose to the corresponding 4D CT phases as predicted by the
PMTM: full inhale, 80% inhale, 60% inhale, 40% inhale, 20% inhale, Full exhale,
20% exhale, 40% exhale, 60% exhale, and 80% exhale. Figure 4.10 displays the
resulting composite treatment plan dose using each of the 4D CT phase shown
below.
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Figure A.1. Field 1&2 – Dose delivered to 80% inhale CT phase
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Figure A.2. Field 1&2 – Dose delivered to 60% inhale CT phase
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Figure A.3. Field 1&2 – Dose delivered to 40% inhale CT phase
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Figure A.4. Field 1&2 – Dose delivered to 20% inhale CT phase
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Figure A.5. Field 1&2 – Dose delivered to full exhale CT phase
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Figure A.6. Field 1&2 – Dose delivered to 20% exhale CT phase
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Figure A.7. Field 1&2 – Dose delivered to 40% exhale CT phase
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Figure A.8. Field 1&2 – Dose delivered to 60% exhale CT phase
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Figure A.9. Field 1&2 – Dose delivered to 80% exhale CT phase
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